주식/증권
➡️ 중립
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling
요약
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome.